Brief: Cytrx Notes Orphazyme’S Regulatory Update From The FDA On Arimoclomol For Niemann-Pick Disease Type C
18/06/2021 21:33
June 18 (Reuters) - CytRx Corp CYTR.PK :
* CYTRX NOTES ORPHAZYME’S REGULATORY UPDATE FROM THE FDA ON
ARIMOCLOMOL FOR NIEMANN-PICK DISEASE TYPE C
Source text for Eikon: ID:nBw5Wh01Va
Further company coverage: CYTR.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on LadRx
See all newsBrief: Ladrx Issues 2024 Update To Shareholders
Brief: LadRx Completes Non-Dilutive Financing Transaction For Up To $11 Mln With Xoma Corporation
Brief: LadRx Intends To Apply To List Stock On Nasdaq Under Symbol 'LADX'
Brief: LadRx Announces Review Of Strategic Alternatives, Provides Corporate Updates
Brief: CytRx Highlights Orphazyme's Update On Productive Meeting With FDA Regarding Arimoclomol In Niemann-Pick Disease Type C